Clinical differences between influenza A (H1N1) virus and respiratory infection between the two waves in 2009 and 2010 (original) (raw)

Abstract

The purpose of the present retrospective study was to examine the clinical differences between patients hospitalized with H1N1 virus and those hospitalized with nonvirus respiratory tract infection in 2009 and 2010. Methods: Adult patient data were collected from three tertiary hospital centers. Real-time reverse transcriptase polymerase chain reaction testing was used to confirm the diagnosis. We included 106 H1N1-positive patients (52 from 2009 and 54 from 2010). These data were compared with those from 108 patients with H1N1-negative respiratory tract infection (51 patients from 2009 and 57 from 2010). Results: In 2009, the mean age was 36.4 years for H1N1-positive patients versus 46.4 years for H1N1-negative patients, and mean body mass index (BMI) was 26.4 kg/m 2 patients and 28.1 kg/m 2 , respectively. In 2009, seven patients required intubation, six of whom were H1N1-positive. In 2010, the mean age was 43.8 years for H1N1-positive patients versus 60.2 years for H1N1-negative patients, and mean BMI was 32.3 kg/m 2 and 26.9 kg/m 2 , respectively. In 2010, six patients required intubation, three of whom were H1N1-positive. Abnormal chest x-ray findings were found significantly more frequently in H1N1-negative patients than in H1N1-positive patients. Conclusion: In comparison with 2009, H1N1-positive patients in 2010 were older, were more likely to be obese, and had more severe clinical and laboratory perturbations. However, this did not affect their outcomes. H1N1-negative patients were older in comparison with those who were H1N1-positive, and had more severe clinical and laboratory perturbations.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (49)

  1. Update: infections with a swine-origin influenza A (H1N1) virus -United States and other countries, April 28, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(16):431-433.
  2. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25): 2605-2615.
  3. Belshe RB. Implications of the emergence of a novel H1 influenza virus. N Engl J Med. 2009;360(25):2667-2668.
  4. Naffakh N, van der Werf S. April 2009: an outbreak of swine- origin influenza A (H1N1) virus with evidence for human-to-human transmission. Microbes Infect. 2009;11(8-9):725-728.
  5. Gunson RN, Carman WF. During the summer 2009 outbreak of "swine flu" in Scotland what respiratory pathogens were diagnosed as H1N1/2009? BMC Infect Dis. 2011;11:192.
  6. Zarogoulidis P, Glaros D, Kontakiotis T, et al. Health costs from hospitalization with H1N1 infection during the 2009-2010 influenza pandemic compared with non-H1N1 respiratory infections. Int J Gen Med. 2012;5:175-182.
  7. Anderson RM. How well are we managing the influenza A/H1N1 pandemic in the UK? BMJ. 2009;339:b2897.
  8. Jefferson T, Jones M, Doshi P, Del Mar C. Possible harms of oselta- mivir -a call for urgent action. Lancet. 2009;374(9698):1312-1313.
  9. Gerrard J, Keijzers G, Zhang P, Vossen C, Macbeth D. Clinical diag- nostic criteria for isolating patients admitted to hospital with suspected pandemic influenza. Lancet. 2009;374(9702):1673.
  10. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Commit- tee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2009;58(RR-8):1-52.
  11. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med. 1999;160(2):397-405.
  12. Diaz A, Barria P, Niederman M, et al. Etiology of community- acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest. 2007;131(3):779-787.
  13. Lim WS, MacFarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implica- tions for management guidelines. Thorax. 2001;56(4):296-301.
  14. Ewig S, Torres A. Severe community-acquired pneumonia. Curr Opin Crit Care. 2002;8(5):453-460.
  15. El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumo- nia in the very elderly. Am J Respir Crit Care Med. 2001;163(3 Pt 1): 645-651.
  16. Bandaranayake D, Jacobs M, Baker M, et al. The second wave of 2009 pandemic influenza A (H1N1) in New Zealand, January-October 2010. Euro Surveill. 2011;16(6):pii 19788.
  17. Keramarou M, Cottrell S, Evans MR, et al. Two waves of pandemic influenza A (H1N1) 2009 in Wales -the possible impact of media coverage on consultation rates, April-December 2009. Euro Surveill. 2011;16(3):pii 19772.
  18. Barr IG, Cui L, Komadina N, et al. A new pandemic influenza A (H1N1) gen- etic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore. Euro Surveill. 2010;15(42):pii 19692.
  19. Ellis J, Galiano M, Pebody R, et al. Virological analysis of fatal influ- enza cases in the United Kingdom during the early wave of influenza in winter 2010/11. Euro Surveill. 2011;16(1):pii 19760.
  20. Maurer-Stroh S, Lee RT, Eisenhaber F, Cui L, Phuah SP, Lin RT. A new common mutation in the hemagglutinin of the 2009 (H1N1) influenza A virus. PLoS Curr. 2010;2:RRN1162.
  21. Hurt AC, Deng YM, Ernest J, et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A (H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill. 2011;16(3):pii 19770.
  22. Shikov AN, Sementsova AO, Demina OK, et al. Genetic variability of isolates of pandemic influenza A virus H1N1 isolated in Russia in 2009. Mol Gen Mikrobiol Virusol. 2011(4):23-29. Russian.
  23. Mir MA, Lal RB, Sullender W, et al. Genetic diversity of HA1 domain of hemagglutinin gene of pandemic influenza H1N1pdm09 viruses in New Delhi, India. J Med Virol. 2012;84(3):386-393.
  24. Kilander A, Rykkvin R, Dudman SG, Hungnes O. Observed associa- tion between the HA1 mutation D222G in the 2009 pandemic influenza A (H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro Surveill. 2010;15(9):pii 19498.
  25. Lackenby A, Moran Gilad J, Pebody R, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A (H1N1)2009 virus, United Kingdom, winter 2010/2011. Euro Surveill. 2011;16(5): pii 19784.
  26. Pontoriero A, Baumeister E, Campos AM, Savy VL. Virological surveil- lance and antiviral resistance of human influenza virus in Argentina, 2005-2008. Rev Panam Salud Publica. 2011;30(6):634-640.
  27. Kawai N, Ikematsu H, Iwaki N, et al. Persistence of pandemic influ- enza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation. J Infect Chemother. 2012;18(2):180-186.
  28. Hong SD, Park SH, Kang SJ, et al. First fatal oseltamivir-resistant 2009 pandemic influenza A (H1N1) case in an adult in Korea. Chonnam Med J. 2011;47(2):127-129.
  29. Zarogoulidis P, Constantinidis T, Steiropoulos P, Papanas N, Zarogoulidis K, Maltezos E. "Are there any differences in clinical and laboratory findings on admission between H1N1 positive and negative patients with flu-like symptoms?". BMC Res Notes. 2011;1(1):141.
  30. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382.
  31. Faix DJ, Sherman SS, Waterman SH. Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;361(7):728-729.
  32. Panagiotopoulos T, Bonovas S, Danis K, et al. Cluster of new influenza A (H1N1) cases in travellers returning from Scotland to Greece -community transmission within the European Union? Euro Surveill. 2009;14(21):pii 19226.
  33. Gioula G, Melidou A, Exindari M, et al. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus in Northern Greece. Hippokratia. 2011;15(3):272-274.
  34. Melidou A, Gioula G, Exindari M, Chatzidimitriou D, Diza E, Malisiovas N. Molecular and phylogenetic analysis of the haemagglu- tinin gene of pandemic influenza H1N1 2009 viruses associated with severe and fatal infections. Virus Res. 2010;151(2):192-199.
  35. Maltezou HC. Nosocomial influenza: new concepts and practice. Curr Opin Infect Dis. 2008;21(4):337-343.
  36. Tsiodras S, Sypsa V, Hatzakis A. The vaccination campaign against 2009 pandemic influenza A (H1N1) and its continued importance in view of the uncertainty surrounding the risk associated with the pandemic. Euro Surveill. 2010;15(3):pii 19468.
  37. Sypsa V, Pavlopoulou I, Hatzakis A. Use of an inactivated vaccine in mitigating pandemic influenza A (H1N1) spread: a modelling study to assess the impact of vaccination timing and prioritisation strategies. Euro Surveill. 2009;14(41):pii 19356.
  38. Sypsa V, Livanios T, Psichogiou M, et al. Public perceptions in rela- tion to intention to receive pandemic influenza vaccination in a random population sample: evidence from a cross-sectional telephone survey. Euro Surveill. 2009;14(49):pii 19437.
  39. Calbo E, Robles A, Sangil A, et al. H1N1 influenza pneumonia and bacterial coinfection. Thorax. 2011;66(12):1091-1092.
  40. Fabbiani M, Sali M, Di Cristo V, et al. Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy. J Med Virol. 2011;83(12): 2057-2065.
  41. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immuno- modulatory effects of macrolide antibiotics -part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration. 2011;81(1):75-87.
  42. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immu- nomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. 2012;68(5):479-503.
  43. Miyamoto D, Hasegawa S, Sriwilaijaroen N, et al. Clarithromycin inhibits progeny virus production from human influenza virus-infected host cells. Biol Pharm Bull. 2008;31(2):217-222.
  44. Bermejo-Martin JF, Kelvin DJ, Eiros JM, Castrodeza J, Ortiz de Lejarazu R. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. J Infect Dev Ctries. 2009;3(3):159-161.
  45. Weinbroum AA, Kluger Y, Ben Abraham R, Shapira I, Karchevski E, Rudick V. Lung preconditioning with N-acetyl-L-cysteine prevents reperfusion injury after liver no flow-reflow: a dose-response study. Transplantation. 2001;71(2):300-306.
  46. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol- containing antioxidant: N-acetylcysteine. Respiration. 1986;50 Suppl 1: 31-42.
  47. Rahamat-Langendoen JC, Tutuhatunewa ED, Scholvinck EH, et al. Influenza in the immediate post-pandemic era: a comparison with seasonal and pandemic influenza in hospitalized patients. J Clin Virol. 2012;54(2):135-140.
  48. Myles PR, Semple MG, Lim WS, et al. Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax. March 14, 2012. [Epub ahead of print.]
  49. Rabagliati R, Labarca J, Siri L, Perez CM, Ferres M. Rates of hospital-acquired influenza due to the pandemic H1N1 virus in 2009, compared with seasonal influenza. Infect Control Hosp Epidemiol. 2011;32(2):198-200.